Alcista
$14.19
Precio del escenario
$10.855
+0.005 (+0.05%)Al cierre
Jackson Acquisition Company II is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It may pursue an initial business combination target in any industry or geographic location, it intends to focus its search for a target business by concentrating its efforts in identifying businesses with a focus on healthcare services, healthcare technology, or otherwise focused on the healthcare industry. The Company neither engaged in any operations nor generated any revenue.
Jackson Acquisition Company II (JACS) is currently trading at $10.85, which is very close to its 52-week high of $10.87, indicating limited upside potential. The RSI is at 57.63, suggesting that the stock is neither overbought nor oversold, which is a neutral indicator. However, the forward P/E ratio is 0, indicating a lack of expected earnings growth, which raises concerns about future profitability. The stock has shown a 5-day change of +0.28% and a year-to-date change of +4.13%, reflecting modest performance. The main risk is the current ratio, which has dropped to 0.77, indicating potential liquidity issues. Therefore, while the stock shows some stability, the lack of growth indicators and the liquidity risk suggest that it may be prudent to hold rather than buy at this time.
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Jackson Acquisition Company II is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It may pursue an initial business combination target in any industry or geographic location, it intends to focus its search for a target business by concentrating its efforts in identifying businesses with a focus on healthcare services, healthcare technology, or otherwise focused on the healthcare industry. The Company neither engaged in any operations nor generated any revenue. It operates in the Financials sector.
Jackson Acquisition Company II (JACS) is currently trading at $10.85, which is very close to its 52-week high of $10.87, indicating limited upside potential. The RSI is at 57.63, suggesting that the stock is neither overbought nor oversold, which is a neutral indicator. However, the forward P/E ratio is 0, indicating a lack of expected earnings growth, which raises concerns about future profitability. The stock has shown a 5-day change of +0.28% and a year-to-date change of +4.13%, reflecting modest performance. The main risk is the current ratio, which has dropped to 0.77, indicating potential liquidity issues. Therefore, while the stock shows some stability, the lack of growth indicators and the liquidity risk suggest that it may be prudent to hold rather than buy at this time.
Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.